Other
Interest Paid, Net
Alnylam Pharmaceuticals Interest Paid, Net decreased by 43.3% to $64.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 6.9%, from $68.93M to $64.20M. Over 4 years (FY 2021 to FY 2025), Interest Paid, Net shows an upward trend with a 72.6% CAGR.
Analysis
StatementIncome Statement
SectionOther
First reportedQ1 2016
Last reportedQ1 2026Apr 30, 2026
Metric ID:
ms_interest_paid_netHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.16M | $6.16M | $6.16M | $14.12M | $14.94M | $14.87M | $1.30M | $13.91M | $3.22M | $9.55M | $5.44M | $30.95M | $8.16M | $16.15M | $12.33M | $68.93M | $12.57M | $23.89M | $113.32M | $64.20M |
| QoQ Change | — | +0.0% | +0.0% | +129.1% | +5.8% | -0.5% | -91.2% | +967.7% | -76.9% | +196.9% | -43.0% | +468.5% | -73.6% | +98.0% | -23.6% | +459.1% | -81.8% | +90.1% | +374.3% | -43.3% |
| YoY Change | — | — | — | — | +142.4% | +141.3% | -78.9% | -1.5% | -78.5% | -35.8% | +317.7% | +122.4% | +153.6% | +69.1% | +126.5% | +122.8% | +54.1% | +48.0% | +819.0% | -6.9% |
Range$1.30M – $113.32M
CAGR+63.8%
Avg YoY Growth+119.7%
Median YoY Growth+95.8%
Interest Paid, Net at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's interest paid, net?
- Alnylam Pharmaceuticals (ALNY) reported interest paid, net of $64.20M in Q1 2026.
- How has Alnylam Pharmaceuticals's interest paid, net changed year-over-year?
- Alnylam Pharmaceuticals's interest paid, net decreased by 6.9% year-over-year, from $68.93M to $64.20M.
- What is the long-term trend for Alnylam Pharmaceuticals's interest paid, net?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's interest paid, net has grown at a 72.6% compound annual growth rate (CAGR), from $24.66M to $218.71M.